Mirum Pharmaceuticals, Inc.   Report issue

Contributed to NME For profit Phase 2 Phase 3
Founded: San Diego CA United States (2018)

Organization Overview

First Clinical Trial
2019
NCT03905330
First Marketed Drug
2018
cholic acid (cholbam)
First NDA Approval
2021
maralixibat (LIVMARLI)
Last Known Activity
2021

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

MIRUM | Mirum Pharmaceuticals, Inc. | MIRUM PHARMA INC

Active Ingredients

Marketed Drugs (2)

cholic acid (cholbam) (2015)

maralixibat (LIVMARLI) (2021 NDA)

Drugs in Phase 3 Trials (1)

maralixibat (LIVMARLI) (6 trials)

Drugs in Phase 2 Trials (3)

Key: Mirum Pharmaceuticals, Inc. (1) Acquired (2)

conjugated bile acids (1 trial)

glucose (1 trial)

Volixibat (3 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Biliary Atresia (Phase 2)

Cholangitis (Phase 2)

Cholangitis, Sclerosing (Phase 2)

Cholestasis (Phase 3)

Cholestasis, Intrahepatic (Phase 3)

Liver Diseases (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 10
  • # of Trial APIs: 4